Immunome stock sinks after testing of its experimental Covid-19 'cocktail' delayed by FDA
January 11, 2022 at 09:56 AM EST
Immunome filed an investigational new drug application with the FDA in late November seeking approval to begin human testing of the Covid-19 therapy.